M&A Deal Summary |
|
|---|---|
| Date | 2018-11-08 |
| Target | Weisheng |
| Sector | Life Science |
| Buyer(s) |
Vivo Capital
HBM Partners Ascendis Pharma |
| Deal Type | Joint Venture |
SEARCH BY
| Category | Growth Capital Firm |
|---|---|
| Founded | 1996 |
| PE ASSETS | 6.4B USD |
| Size | Mega |
| Type | Sector Focused |
Vivo Capital is a healthcare investment firm focused on opportunities throughout the US and China. Specific areas of interest include biopharmaceuticals, specialty pharmaceuticals, and medical devices. The Firm looks to identify and work with companies at the development and commercial stage products in the US and at the revenue stage in China. Vivo Capital was established in 1997 and is headquartered in Palo Alto, California.
| DEAL STATS | # |
|---|---|
| Overall | 15 of 18 |
| Sector: Life Science M&A | 11 of 13 |
| Type: Joint Venture M&A Deals | 1 of 1 |
| Country: China M&A | 1 of 1 |
| Year: 2018 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-06-02 |
Tricida
South San Francisco, California, United States Tricida is a pharmaceutical company focused on developing and commercializing its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Tricida was founded in 2013 and is based in South San Francisco, California. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-01-04 |
Minerva Surgical
Santa Clara, California, United States Minerva Surgical is a medical technology company focused on developing next-generation technology for treating excessive menstrual bleeding. Minerva Surgical was formed in 2008 and is based in Santa Clara, California. |
Buy | - |
| Category | Private Equity Firm |
|---|---|
| Founded | 2001 |
| PE ASSETS | 2.1B USD |
| Size | Large |
| Type | Sector Focused |
HBM Partners is a private investment firm focused on investing in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. HBM looks to invest $5 to $50 million per transaction and will consider private and public companies. HBM Partners was established in 2001 and is headquartered in Zug, Switzerland.
| DEAL STATS | # |
|---|---|
| Overall | 25 of 65 |
| Sector: Life Science M&A | 19 of 56 |
| Type: Joint Venture M&A Deals | 1 of 1 |
| Country: China M&A | 3 of 7 |
| Year: 2018 M&A | 7 of 8 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-10-12 |
Cardialen
Minneapolis, Minnesota, United States Cardialen is an early-stage medical device company dedicated to advancing implantable cardioversion and defibrillation using low energy for use as a first-line therapy to restore normal heart rhythm and may reduce the potential for high-energy defibrillation shocks. Cardialen was founded in 2008 and is based in Minneapolis, Minnesota. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-11-26 |
Adrenomed
Berlin, Germany Adrenomed is a privately-financed, clinical-stage biopharmaceutical company with a clear mission: to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Adrenomed was founded in 2009 and is based in Berlin, Germany. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 2006 |
| Sector | Life Science |
| Employees | 1,017 |
| Revenue | 364M EUR (2024) |
Ascendis Pharma is a pharmaceutical company developing improved, patentable versions of high-value drugs. The company’s proprietary TransCon technology is used to generate drug candidates that are more effective and have lower risk than existing drugs, and have new patent life. Ascendis Pharma was founded in 2006 and is based in Hellerup, Denmark.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Joint Venture M&A Deals | 1 of 1 |
| Country: China M&A | 1 of 1 |
| Year: 2018 M&A | 1 of 1 |
